Table 5.
Interventions of SRs in COVID-19 treatment
| Items | N | Percentage (%) |
|---|---|---|
| Report | ||
| Yes | 186 | 98.41 |
| No | 3 | 1.59 |
| Interventions | ||
| Antiviral therapy | 81 | 42.86 |
| Not reported | 11 | 5.82 |
| Chloroquine/hydroxychloroquine | 26 | 13.76 |
| Interferon | 5 | 2.65 |
| Lobinavir/ritonavir | 11 | 5.82 |
| Ribavirin | 5 | 2.65 |
| Remdesivir | 12 | 6.35 |
| Abiron | 4 | 2.12 |
| Favipiravir | 5 | 2.65 |
| Abidor | 2 | 1.06 |
| Respiratory support | 16 | 8.47 |
| Circulatory support | 11 | 5.82 |
| Plasma therapy for convalescent patients | 11 | 5.82 |
| Immunotherapy | 9 | 4.76 |
| TCM treatment | 9 | 4.76 |
| Rehabilitation treatment | 5 | 2.65 |
| Anti-inflammatory treatment | 16 | 8.47 |
| Other treatments | 31 | 16.40 |